pharma · Major Depressive Disorder · Migraine · AXSM
Axsome Therapeutics
Axsome Therapeutics is a pharma organization headquartered in New York, USA. It trades on NYSE under ticker AXSM. Primary therapeutic focus areas include Major Depressive Disorder, Migraine, Agitation in Patients With De
One World Trade Center, New York, NY 10007, US HQ
2012 Founded
981 Employees
Public company Type
AXSM · NYSE Ticker
Company details
- Status
- Public
- HQ
- One World Trade Center, New York, NY 10007, US
- Founded
- 2012
- Employees
- 981
- Programs
- 28
- Drugs
- 12
- Patents
- 162
Solriamfetol 300 mg
Phase 3 · small molecule · Major Depressive Disorder
Solriamfetol 300 mg for Major Depressive Disorder is a Phase 3 program (small_molecule) at Axsome Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code SOL-MDD-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Axsome Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Major Depressive Disorder
- Status
- completed
- Trials
- 1